Provided by Tiger Fintech (Singapore) Pte. Ltd.

IN8bio, Inc.

0.1609
+0.00332.09%
Post-market: 0.16290.0020+1.24%19:57 EDT
Volume:467.53K
Turnover:74.62K
Market Cap:13.07M
PE:-0.28
High:0.1649
Open:0.1582
Low:0.1568
Close:0.1576
Loading ...

IN8bio Raised to Buy From Hold by Jones Trading

Dow Jones
·
12 Feb

IN8bio upgraded to Buy from Hold at JonesResearch

TIPRANKS
·
11 Feb

JonesResearch upgrades IN8bio to Buy on ‘impressive’ AML data

TIPRANKS
·
11 Feb

IN8bio, Inc. : Jonestrading Raises to Buy Rating; Raises Target Price to $1.2

THOMSON REUTERS
·
11 Feb

IN8bio Says Data Show All Acute Myeloid Leukemia Patients in Early-Stage Study Remain Relapse-Free; Shares Up Pre-Bell

MT Newswires Live
·
11 Feb

IN8bio reports updated results from Phase 1 trial of INB-100

TIPRANKS
·
11 Feb

IN8bio, Inc. - 100% of Aml Patients Remain in Complete Remission

THOMSON REUTERS
·
11 Feb

IN8bio, Inc. - Inb-100 Patients Show Prolonged Remissions Supported by Gamma-Delta T Cells

THOMSON REUTERS
·
11 Feb

IN8bio Reports Updated Positive Results From Phase 1 Trial of Inb-100 in Leukemia Patients

THOMSON REUTERS
·
11 Feb

IN8bio, Inc. - Aml Patients Show One-Year Pfs and Os Exceeding Control Groups

THOMSON REUTERS
·
11 Feb

IN8bio, Inc. - Inb-100 Well-Tolerated With No Crs or Neurotoxicity

THOMSON REUTERS
·
11 Feb

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients

GlobeNewswire
·
11 Feb

IN8bio to Present at Biotech Showcase 2025 in San Francisco

GlobeNewswire
·
06 Jan

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of Inb-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

THOMSON REUTERS
·
10 Dec 2024

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

GlobeNewswire
·
10 Dec 2024

IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference

GlobeNewswire
·
02 Dec 2024

Analysts Offer Insights on Healthcare Companies: IN8bio (INAB), Vigil Neuroscience Inc (VIGL) and Outlook Therapeutics (OTLK)

TIPRANKS
·
28 Nov 2024

Mizuho Securities Remains a Buy on IN8bio (INAB)

TIPRANKS
·
27 Nov 2024

JonesTrading Sticks to Its Hold Rating for IN8bio (INAB)

TIPRANKS
·
26 Nov 2024

IN8bio Price Target Announced at $8.00/Share by HC Wainwright & Co.

Dow Jones
·
26 Nov 2024